Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Oncology Reports|February 27, 2019
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical DevelopmentJessica Gillen, Debra Richardson, Kathleen Moore
Journal of Public Health Research|September 11, 2020
Using system mapping to help plan and implement city-wide action to promote physical activityNick Cavill, Debra Richardson, Mark Faghy, et al.
Gynecologic Oncology|June 21, 2012
Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvementTodd Boren, Jayanthi Lea, Siobhan Kehoe, et al.
International Journal of Radiation Oncology, Biology, Physics|November 8, 2019
A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical CancerKevin Albuquerque, Vasu Tumati, Jayanthi Lea, et al.
Gynecologic Oncology|January 14, 2017
The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatmentSarah Bedell, Dustin Manders, Siobhan Kehoe, et al.
Gynecologic Oncology|July 8, 2010
The prognostic significance of the triple negative phenotype in endometrial cancerRajul Kothari, Carl Morrison, Debra Richardson, et al.
Neurological Research|February 24, 2004
Innate spatial-temporal reasoning and the identification of geniusMatthew R Peterson, Doreen Balzarini, Mark Bodner, et al.
Brachytherapy|March 24, 2016
Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignanciesVasu Tumati, Michael R Folkert, Sandra Lawson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group studyDana Chase, Helen Q Huang, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Pageof 2